NAFLD/MASH Cell Models and Lipotoxicity
Three compartments, one of which is easy to model
MASH is a tissue-level disease with three compartments. A monoculture contains one of them.
| Compartment | What it contributes | Modelled by |
|---|---|---|
| Parenchymal | Steatosis, ballooning, hepatocellular injury | Hepatocyte monoculture |
| Non-parenchymal | Inflammation, stellate activation, fibrosis | Co-culture or conditioned medium |
| Systemic | Substrate supply, insulin, adipose-derived fatty acids | Absent in any dish |
Important distinction. A monoculture can generate steatosis and a form of lipotoxic injury. It cannot generate fibrosis, because fibrosis is produced by activated stellate cells laying down matrix. A paper reporting "MASH model" on the basis of triglyceride accumulation and LDH release has modelled the first compartment only, and the name should say so.
Which hepatocyte
| Model | Metabolic fidelity | Best used for | Main limitation |
|---|---|---|---|
| HepG2 | Low; tumour-derived, glycolytic, low CYP and low albumin | Convenience screens | Retains fetal-like metabolism; poor insulin response |
| Huh7 | Low–moderate | Reporter assays, some lipid work | Similar limitations; heterogeneous |
| Primary human hepatocyte | High initially | Short-term mechanistic work | Dedifferentiates within days; scarce |
| iPSC-derived hepatocyte | Moderate; improving | Genotype-defined, patient-specific questions | Fetal-like; immature drug metabolism |
| Hepatocyte–NPC co-culture / organoid | Higher, with architecture | Fibrosis and inflammation claims | Cost, reproducibility, throughput |
Caveat on immortalised lines. HepG2 and Huh7 are selected for proliferation, and proliferation and hepatocyte metabolic function are partly opposing programmes. The same selection that makes them convenient removes much of the metabolic phenotype being studied. A result that depends on gluconeogenic or lipogenic flux in HepG2 should be confirmed in a primary or iPSC-derived system before it is generalised.
Caveat on primary cells. Dedifferentiation is rapid: albumin and CYP expression fall within 48–72 hours in conventional monolayer. A 5-day treatment protocol in primary hepatocytes is therefore measuring a partially dedifferentiated cell, and the phenotype may reflect that transition rather than the treatment.
The fatty acid ratio is the design decision
| Composition | Dominant outcome | What it models |
|---|---|---|
| Oleate alone | Triglyceride storage, large droplets, little toxicity | Steatosis without injury |
| Palmitate alone | ER stress, apoptosis, small droplets | Lipotoxicity, not steatosis |
| Oleate : palmitate 2:1 | Storage with modest injury | The common "MASH" induction |
| Oleate : palmitate 1:1 | Intermediate | Higher injury, less storage |
| Saturated + free cholesterol | Cholesterol crystal formation, inflammasome | A specific sub-phenotype |
The ratio is not a technical detail; it determines which disease feature appears. Oleate is efficiently esterified and stored; palmitate is poorly esterified relative to its flux and is routed into ceramide, DAG and ER stress. Adding oleate therefore protects against palmitate toxicity while increasing triglyceride — the same paradox the disease pillar describes, reproduced in a dish.
Important distinction. Total triglyceride and toxicity move in opposite directions across this series. A compound that lowers triglyceride in a 2:1 model may be doing so by blocking esterification, which increases the free fatty acid and DAG pools. The measured improvement would then be the mechanism of harm.
Readouts, and what each one actually reports
| Readout | Reports | Does not report |
|---|---|---|
| Triglyceride mass (colorimetric) | Total esterified lipid | Species, compartment, toxicity |
| BODIPY 493/503 | Neutral lipid area and droplet count | Lipid species; may report droplet size only |
| Oil Red O | Neutral lipid, endpoint | Dynamics; requires fixation |
| Lipidomics | Species composition | Flux; a static snapshot |
| LDH release | Membrane integrity | Which death programme |
| Caspase-3/7 | Apoptotic execution | Ferroptosis or pyroptosis |
| CHOP, XBP1s | ER stress response | Whether ER stress is the cause of death |
| TG secretion (apoB, VLDL) | Export capacity | Hepatic retention, which is the difference |
Readout note. The last row is the one that distinguishes MASH from simple steatosis at the cellular level: retention is what happens when synthesis and uptake exceed export and oxidation. A model that increases triglyceride without measuring export has not shown retention.
Timing
Steatosis accumulates over 24–48 hours in most protocols; injury markers rise at 48–72 hours; inflammatory and fibrotic readouts need days to weeks and a co-culture. A 6-hour palmitate exposure is a biophysics experiment about membrane saturation, not a disease model, and reporting it as an MASH model mislabels the timescale.
Caveat on "ballooning". Ballooning degeneration is a histological diagnosis that depends on cell swelling, cytoskeletal redistribution and three-dimensional architecture. Two-dimensional culture can produce enlarged, lipid-laden cells, but calling them ballooned hepatocytes asserts a histological category that the system cannot establish.
The fibrosis boundary
If the claim involves fibrosis, the model needs stellate cells.
| Component | Requirement | Readout |
|---|---|---|
| Stellate cell source | LX-2 (immortalised) or primary human HSC | α-SMA, COL1A1 |
| Activation | Co-culture with lipid-loaded hepatocytes, or conditioned medium | α-SMA protein, not transcript alone |
| Matrix deposition | 3D or long-term co-culture | Hydroxyproline, second-harmonic imaging |
| Architecture | Organoid or precision-cut slice | Bridging septa — rarely achieved in vitro |
Important distinction. α-SMA expression marks activation, not fibrosis. Fibrosis is matrix deposition with architectural change. Most in vitro systems can reach activation; few reach deposition; almost none reach architecture. A claim about "anti-fibrotic" activity from a 2D co-culture is a claim about stellate activation.
Failures that recur
- • Palmitate-only protocol described as a steatosis model. It is an injury model.
- • Triglyceride used as the efficacy endpoint. It can fall while toxicity rises.
- • No viability-normalised lipid measurement. Fewer cells can look like less fat per well but more per cell.
- • BSA concentration unreported. Free fatty acid concentration depends on the molar ratio, not the nominal concentration.
- • Two-day treatment called chronic. MASH develops over years.
- • HepG2 used for an insulin-sensitivity claim. The line has weak insulin responsiveness and low hepatic function.
- • Fibrosis inferred from a monoculture. No stellate cells, no matrix.
Where this connects
- • Lipid pillar supplies the species logic: total triglyceride is the least informative measurement, and esterification is protective.
- • Disease pillar supplies the readout frame: steatosis, activity and fibrosis are three separate claims with three separate readouts.
- • Glucose pillar supplies the lipogenic substrate link: high glucose and insulin drive de novo lipogenesis, which is why "glucolipid" protocols combine them.
- • Operationally, the protocol parameters — seeding, fatty acid preparation, refresh schedule, QC gates — are in the companion article on building a hepatocyte lipid droplet model.
Scientific interpretation and experimental design
- • Name the compartment. A monoculture models parenchymal disease only.
- • The fatty acid ratio is the experiment. Oleate stores, palmitate injures.
- • Triglyceride is not the endpoint. Measure species and export.
- • Normalise lipid to cell number. Otherwise toxicity reads as less fat.
- • Report BSA molar ratio. Nominal fatty acid concentration is not free concentration.
- • Ballooning is histological. Two-dimensional culture cannot establish it.
- • Fibrosis needs stellate cells and matrix. α-SMA is activation, not fibrosis.
Selected references for further reading
- • Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine. 2018;24:908–922.
- • Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.
- • Listenberger LL, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. PNAS. 2003;100:3077–3082.
- • Ricchi M, et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. Journal of Gastroenterology and Hepatology. 2009;24:830–840.
- • Febbraio MA, et al. Preclinical models for studying NASH-driven HCC: how useful are they? Cell Metabolism. 2019;29:18–26.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »